NCT00448071

Pharmacokinetic and Pharmacodynamic Effects of MTR107 in End-Stage Renal Disease (ESRD) Patients

A Phase II, Randomized Double Blind Placebo-Controlled, Dose Escalating Study to Determine Pharmacokinetic and Pharmacodynamic Effects of MTR107 in End-Stage Renal Disease (ESRD) Patients

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 12 (planned)
• Sponsor: Wolfson Medical Center · Other Government
• Sex: All
• Age: 20 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

MTR107 effect on blood pressure throught the dialysis procedure and its ability to prevent Intra dialytic Hypotension

Detailed description

The present clinical trial aims to investigate and provide a more precise characterization of the pharmacokinetic and pharmacodynamic profile of MTR107 in a population of ESRD patients predisposed to developing intradialytic hypotension. The study is also designed as a dose esclating study aiming to assess MTR107 safety.

Conditions

• Hypotension
• End Stage Renal Disease
• Intra Dialytic Hypotension

Interventions

Type	Name	Description
DRUG	MTR107

Timeline

• Start date: 2006-05-01
• Completion: 2007-03-01
• First posted: 2007-03-15
• Last updated: 2007-03-15

Locations

2 sites across 1 country: Israel